Ireland-based leading healthcare product maker Covidien plc (COV) will present new data on its hernia and abdominal wall repair products at Hernia Repair 2011, the annual meeting of the American Hernia Society (“AHS”), slated to be held in San Francisco from March 16–19, 2011.
Covidien will highlight its products at Hernia Repair 2011 in two podium presentations and nine poster sessions as well as self-sponsored symposia. The company has come out with a long list of events that will feature updated results from clinical studies, to be presented by surgeons, supporting the potential of its products in mitigating post-surgical pain and complications in hernia and abdominal wall repair procedures.
Presentations by surgeons at Hernia Repair 2011 will include update on the safety and efficacy, and benefits of the company’s hernia repair product Parietex ProGrip self-fixating mesh. Other products to be featured include the AbsorbaTack absorbable fixation device for laparoscopic inguinal (groin) hernia repair and Permacol Biologic Implant for the repair of abdominal wall defects.
Covidien is a leading global healthcare products company that develops and markets medical solutions for better patient outcomes. The company’s core medical devices business faces stiff competition from Johnson & Johnson (JNJ), Becton Dickinson (BDX) and C.R. Bard (BCR).
Covidien boasts of a well diversified product and technology portfolio. The company remains committed to rolling out new products and technologies, focusing on fast-growing markets, and boosting market share in core segments through investments in sales and marketing infrastructure.
The acquisition of eV3 in July 2010 has bolstered Covidien’s foothold in the peripheral vascular and neurovascular markets.Moreover, the divestiture of its specialty chemicals and sleep therapy product line has enabled Covidien to rationalize its product portfolio and reallocate resources to faster-growing, higher-margin businesses.
However, Covidien’s Pharmaceuticals business remains challenged by aggressive competition and pricing pressure which has contributed to erosion in generic products sales. Moreover, its hernia repair franchise has challenges ahead as C.R. Bard continues to strengthen its foothold in this market with new products.
BARD C R INC (BCR): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
Zacks Investment Research
